Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Larimar Therapeutics ( (LRMR) ) has provided an update.
On May 14, 2026, Larimar Therapeutics reported first-quarter 2026 results and detailed regulatory and clinical progress for nomlabofusp in Friedreich’s ataxia. The company highlighted its intention to begin a rolling biologics license application in June 2026, following supportive FDA feedback on using frataxin as a surrogate endpoint and initiating a global confirmatory Phase 3 trial in mid-2026.
Larimar noted cross-species data published in a peer-reviewed journal showing nomlabofusp-driven increases in frataxin levels across tissues, bolstering the case for skin frataxin as a surrogate biomarker. Financially, it ended March 31, 2026, with $200.4 million in cash, cash equivalents and marketable securities after a February equity offering, reporting a quarterly net loss of $29.6 million and projecting a cash runway into the second quarter of 2027 as it advances toward a potential first-in-class therapy for Friedreich’s ataxia.
The most recent analyst rating on (LRMR) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.
Spark’s Take on LRMR Stock
According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.
Score is held back mainly by weak financial performance (no revenue, sharply rising losses and cash burn, and equity erosion). Offsetting factors include favorable corporate catalysts (Breakthrough Therapy Designation and a targeted 2026 BLA timeline) plus improved liquidity from recent financing, while technicals are mixed with neutral momentum and a potentially oversold signal.
To see Spark’s full report on LRMR stock, click here.
More about Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Its lead candidate, nomlabofusp, is being developed as a potential disease-modifying therapy for Friedreich’s ataxia, and the company aims to leverage its intracellular delivery platform to design additional fusion proteins targeting other rare disorders.
Average Trading Volume: 4,381,220
Technical Sentiment Signal: Sell
Current Market Cap: $429M
Learn more about LRMR stock on TipRanks’ Stock Analysis page.